Peak VO2 maintained in HF patients on IV iron therapy - PACE-CME

Peak VO maintained in HF patients on IV iron therapy

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Changing disease characteristics of cardiac amyloidosis
Changing disease characteristics of cardiac amyloidosis
ESC Heart Failure 2025
Changing disease characteristics of cardiac amyloidosis
- Peter-Paul Zwetsloot, MD, PhD
Uptake of GDMT in HFrEF: from prescriptions to patient adherence and persistence
Uptake of GDMT in HFrEF: from prescriptions to patient adherence and persistence
ESC Heart Failure 2025
Uptake of GDMT in HFrEF: from prescriptions to patient adherence and persistence
- Felix Lindberg, MD, PhD
Greater reductions in NT-proBNP with dapagliflozin/spironolactone combination therapy in HFmrEF/HFpEF
Greater reductions in NT-proBNP with dapagliflozin/spironolactone combination therapy in HFmrEF/HFpEF
ESC Heart Failure 2025
Greater reductions in NT-proBNP with dapagliflozin/spironolactone combination therapy in HFmrEF/HFpEF
- João Pedro Ferreira, MD, PhD
Simplified one-step titration of vericiguat in patients with HF
Simplified one-step titration of vericiguat in patients with HF
ESC Heart Failure 2025
Simplified one-step titration of vericiguat in patients with HF
- Stephen J. Greene, MD